as 05-30-2025 4:00pm EST
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Founded: | 1994 | Country: | France |
Employees: | N/A | City: | N/A |
Market Cap: | 127.2B | IPO Year: | N/A |
Target Price: | $62.50 | AVG Volume (30 days): | 2.3M |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | Dividend Payout Frequency: | Annual | |
EPS: | 5.45 | EPS Growth: | 39.56 |
52 Week Low/High: | $45.80 - $60.12 | Next Earning Date: | 07-24-2025 |
Revenue: | $48,817,552,946 | Revenue Growth: | -2.42% |
Revenue Growth (this year): | 3.39% | Revenue Growth (next year): | 7.05% |
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
MT Newswires
19 hours ago
Investor's Business Daily
19 hours ago
MT Newswires
19 hours ago
Benzinga
20 hours ago
The Wall Street Journal
20 hours ago
MT Newswires
21 hours ago
Reuters
21 hours ago
The Wall Street Journal
a day ago
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.